Apollon Wealth Management LLC Acquires 1,793 Shares of Boston Scientific Co. (NYSE:BSX)

Apollon Wealth Management LLC boosted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 9.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,355 shares of the medical equipment provider’s stock after buying an additional 1,793 shares during the quarter. Apollon Wealth Management LLC’s holdings in Boston Scientific were worth $1,818,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Boston Scientific by 4.4% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider’s stock worth $345,205,000 after purchasing an additional 173,034 shares during the period. Mechanics Bank Trust Department purchased a new stake in Boston Scientific in the fourth quarter worth $415,000. Highland Capital Management LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at $4,887,000. Brookstone Capital Management lifted its position in shares of Boston Scientific by 23.7% during the 4th quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider’s stock valued at $9,455,000 after buying an additional 20,307 shares during the last quarter. Finally, Beacon Investment Advisory Services Inc. grew its stake in shares of Boston Scientific by 31.7% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider’s stock worth $1,744,000 after acquiring an additional 4,702 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 6,528 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $104.97, for a total value of $685,244.16. Following the completion of the sale, the executive vice president now directly owns 26,449 shares in the company, valued at $2,776,351.53. This trade represents a 19.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares in the company, valued at $560,103.60. This trade represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,830 shares of company stock valued at $5,149,969 in the last 90 days. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on BSX shares. Stifel Nicolaus upped their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a report on Thursday, February 6th. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, January 29th. Royal Bank of Canada raised their target price on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Sanford C. Bernstein upped their price target on Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Finally, UBS Group raised their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and a consensus target price of $107.39.

Boston Scientific Stock Up 0.9 %

BSX opened at $106.15 on Tuesday. Boston Scientific Co. has a 12 month low of $64.54 and a 12 month high of $107.17. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The business’s 50-day moving average price is $94.88 and its 200-day moving average price is $87.28. The company has a market cap of $156.44 billion, a P/E ratio of 84.92, a P/E/G ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. On average, equities analysts expect that Boston Scientific Co. will post 2.83 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.